Restoring Health
& Extending Life
At The Heart Of Innovation
A Global Player In Minimally Invasive Structural Heart Devices
From Our Founders
DR. HON. PROF. KATHARINA KISS
CHIEF EXECUTIVE OFFICER
As a practicing cardiologist for over 20 years, I’ve managed care for thousands of patients suffering from heart valve disease with limited treatment options. As the CEO of Products & Features, my team and I are laser-focused on developing structural heart technologies that are designed for procedural ease and enhance patients’ quality of life. The TricValve system is a revolutionary innovation born from this focus on patients and physicians.
DR. PROF. SIEGFRIED EINHELLIG
COO & PRESIDENT
Great engineering equals simple solutions to complex problems. This phrase has guided my journey as an engineer and innovator. I’ve successfully launched several med-tech companies to meet the needs of patients with cardiovascular disease. P&F is the leader in innovating unique valve leaflet technology, an achievement that has been acknowledged by the FDA by granting TricValve Breakthrough Device Status. TricValve is unique in the sense that our technology allows for short intervention times combined with long device durability, thus providing benefits for patients, cardiologists, and healthcare systems alike.
Established and Fully Integrated Global Value Chain
P&F Products & Features is fully integrated with our in-house production process, from raw material to finished product, including dry pericardium, via our Brazilian facility.
R&D
R&D
In-house research & development with full capabilities
PRODUCTION
PRODUCTION
Nitinol stents designed by P&F are laser cut in Germany and shipped to Brazil for tissue attachment and pre-mounting
ASSEMBLY
ASSEMBLY
Delivery systems are premounted, packaged and shipped to Germany
QUALITY TESTING
QUALITY TESTING
LOGISTICS
LOGISTICS
Distribution to around 50 countries where P&F TricValve is approved for use
Engineering Life-Long Solutions
P&F Products & Features is poised for growth with a global, end-to-end approach across the entire value chain. With operation facilities in Germany, Portugal, Spain, and Brazil, our research and development capabilities are the foundation of our approach to innovation. While developing new products and enhancing existing ones, we aim to leverage these capabilities to generate distinctive value and expand access to state-of-the-art technology for patients and healthcare providers worldwide.
News & Resources
Press Releases, Publications and News, Downloads, and the Latest Media from P&F Products & Features
P&F USA secures FDA approval for expansion of the TRICAV I study for severe Tricuspid Regurgitation
On December 19, 2024, the US Food and Drug Administration (FDA) approved the expansion of the TRICAV I study for the TricValve® Transcatheter Bicaval Valve System* from 15 patients to 50 patients
Bicaval TricValve Tricuspid Regurgitation: Late-Breaking PCR London Valves 2024
Source DATA presented at PCR London Valves 2024 showed that caval valve implantation (CAVI) with the TricValve system demonstrates an acceptable safety profile and significant clinical benefits in highly comorbid patients with severe
More minimally invasive treatment options available in S’pore for patients with leaky heart valve
SINGAPORE – Patients with leaky heart valve have more minimally invasive options to treat the condition, after two new procedures were introduced at the National Heart Centre Singapore (NHCS). Also known as